Evaluating a new imaging method for clear cell renal cell carcinoma

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This clinical trial aims to assess the diagnostic value of a specific probe, 68Ga-C1, in PET/CT imaging for patients with clear cell renal cell carcinoma. The study will compare the effectiveness of 68Ga-C1 PET/CT imaging against the standard 18F-FDG PET/CT imaging in diagnosing renal masses. Additionally, it will evaluate the safety, tolerability, and radiation dosimetry associated with the use of 68Ga-C1. The trial focuses on Chinese patients with either confirmed or suspected clear cell renal cell carcinoma.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Signed written informed consent；
2. Age ≥18；
3. Patients with confirmed or suspected clear cell renal cell carcinoma;
4. Expected survival ≥6 months.

Exclusion Criteria:

1. Renal mass is known to be a metastasis of another primary tumor;
2. Have other malignancies that require treatment;
3. Have received chemotherapy, radiotherapy, or immunotherapy within 4 weeks;
4. Renal insufficiency with glomerular filtration rate (GFR) ≤ 60 mL/min/1.73 m²;
5. Pregnant and lactating women or female patients plan to become pregnant within 6 months;
6. Uncontrolled psychiatric disorders;
7. Vulnerable population (e.g., being in detention) or have a serious non-malignant disease (e.g., infectious disease, autoimmune disease, or metabolic disease).

Where it's running

• Peking University First Hospital
  Beijing, Beijing Municipality, China Recruiting

Study contacts

• Principal investigator: Kan Gong — Peking University First Hospital
• Study coordinator: Kan Gong
• Email: kan.gong@bjmu.edu.cn
• Phone: (86)-010-83572075

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Cadonilimab and Lenvatinib in advanced kidney cancer

  This study tests whether Cadonilimab plus Lenvatinib can help adults with unresectable, advanced renal cell carcinoma, especially clear cell type, after prior treatments.

  Recruiting Phase 2 Cancer Institute and Hospital, Chinese Academy of Medical Sciences · Beijing, Panjiayuan Nanli · NCT07909265

• 68Ga-XHER2 PET/CT imaging to see HER2 in solid tumors

  A noninvasive PET/CT imaging test using 68Ga-XHER2 is being tried to see if it reflects HER2 levels in solid tumors.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885436

• 68Ga-XMFH01 PET/FL imaging to guide prostate cancer surgery

  This study tests a new dual-modality imaging probe, 68Ga-XMFH01, to preoperatively detect prostate cancer and guide the surgeon with fluorescence during operations in adults with newly diagnosed prostate cancer.

  Recruiting The First Affiliated Hospital of Xiamen University · Xiamen, Fujian · NCT07885423

• CAIX-targeted PET/CT imaging in solid tumors

  Researchers are testing a CAIX-targeted PET/CT imaging agent to see if it detects and reflects CAIX levels in solid tumors like clear cell renal cell carcinoma, NSCLC, and breast cancer.

  Recruiting Zhongnan Hospital · Wuhan, Hubei · NCT07833085

• Immune cell therapy for advanced clear cell kidney cancer

  This study tests a patient's own tumor-infiltrating lymphocytes (TIL) therapy, given after conditioning with chemotherapy and then interleukin-2, in adults with advanced clear cell renal cell carcinoma who have tried prior treatments.

  Recruiting at 2 sites Phase 1 Hangzhou Huasai Biomedicine Co., Ltd. · Beijing and 1 other locations · NCT07770802

• Theranostic pair labeled PD-32766D/T in CA9-positive clear cell kidney cancer

  This study tests a matching diagnostic agent PD-32766D and a therapeutic agent PD-32766T in adults with CA9-expressing clear cell renal cell carcinoma to see if the treatment is safe and shows signs of effect.

  Recruiting Phase 1 PeptiDream Inc. · Omaha, Nebraska · NCT07688187

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.